Stay updated on Clinical Trial of IL-2 + Nivolumab in RCC
Sign up to get notified when there's something new on the Clinical Trial of IL-2 + Nivolumab in RCC page.

Latest updates to the Clinical Trial of IL-2 + Nivolumab in RCC page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include the term 'Renal Cell Carcinoma' and a new revision number, v2.15.0, while significant details about the clinical trial, including the study design and inclusion/exclusion criteria, have been removed.SummaryDifference35%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Clinical Trial of IL-2 + Nivolumab in RCC
Enter your email address, and we'll notify you when there's something new on the Clinical Trial of IL-2 + Nivolumab in RCC page.